Systematic review of economic evaluations of aromatase inhibitors in estrogen receptor-positive breast cancer: quality evaluation
Abstract Background Breast cancer (BC) is a leading cause of premature death in women and the most expensive malignancy to treat. Since the introduction of targeted therapies has resulted in changes to BC therapy practices, health economic evaluations have become more important in this area. Taking...
Saved in:
Main Authors: | Maha F. Althuwaibi (Author), Cristina Fernandez-Garcia (Author), Louise Hayes (Author), Richard McNally (Author), Diarmuid Coughlan (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2023-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Aromatase inhibitor therapy in recurrent, estrogen-receptor positive uterine serous carcinoma: A case report
by: Omar Najjar, et al.
Published: (2020) -
Progestin and aromatase inhibitor therapy in recurrent, estrogen/progestin receptor positive uterine carcinosarcoma: A case report
by: Angela L. Liang, et al.
Published: (2021) -
Cholesterol de novo biosynthesis: a promising target to overcome the resistance to aromatase inhibitors in postmenopausal patients with estrogen receptor-positive breast cancer
by: Danila Coradini, et al.
Published: (2023) -
Towards a New Generation of Hormone Therapies: Design, Synthesis and Biological Evaluation of Novel 1,2,3-Triazoles as Estrogen-Positive Breast Cancer Therapeutics and Non-Steroidal Aromatase Inhibitors
by: Huda R. M. Rashdan, et al.
Published: (2024) -
Aromatase inhibitor strategies in metastatic breast cancer
by: Heather L McArthur, et al.
Published: (2009)